Cargando…

Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea

BACKGROUND: Parkinson’s disease (PD) and drug-induced parkinsonism (DIP) are the major diseases of parkinsonism. To better understand parkinsonism, we aimed to assess the prevalence and incidence of PD and DIP in Korea from 2012 to 2015. METHODS: We used the Health Insurance Review and Assessment Se...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sola, Kim, Siin, Kim, Hyungtae, Shin, Hae-Won, Na, Kyoung-Sae, Suh, Hae Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805681/
https://www.ncbi.nlm.nih.gov/pubmed/31640652
http://dx.doi.org/10.1186/s12889-019-7664-6
_version_ 1783461448780873728
author Han, Sola
Kim, Siin
Kim, Hyungtae
Shin, Hae-Won
Na, Kyoung-Sae
Suh, Hae Sun
author_facet Han, Sola
Kim, Siin
Kim, Hyungtae
Shin, Hae-Won
Na, Kyoung-Sae
Suh, Hae Sun
author_sort Han, Sola
collection PubMed
description BACKGROUND: Parkinson’s disease (PD) and drug-induced parkinsonism (DIP) are the major diseases of parkinsonism. To better understand parkinsonism, we aimed to assess the prevalence and incidence of PD and DIP in Korea from 2012 to 2015. METHODS: We used the Health Insurance Review and Assessment Service database, which covers the entire population in Korea. We used claims during 2011–2015 to assess epidemiology of PD and DIP during 2012–2015. Retrospective cross-sectional study design was employed to assess prevalence, whereas retrospective cohort study design was used to determine incidence. Patients with at least one claim with ICD-10 G20 and who received antiparkinsonian drugs for at least 60 days were classified as having PD. We excluded patients with antiparkinsonian drugs that can be used for indications other than PD. Patients with at least one claim with ICD-10 G211 or G251 during the prescription period of drugs that are frequently related with DIP were classified as having DIP. Incident cases had a disease-free period of 1 year before diagnosis. To evaluate the significance of changes in the prevalence or incidence over time, Poisson regression was used to determine p for trend. RESULTS: The prevalence of PD increased from 156.9 per 100,000 persons in 2012 to 181.3 per 100,000 persons in 2015 (p for trend< 0.0001). The incidence of PD decreased steadily from 35.4 per 100,000 person-years in 2012 to 33.3 per 100,000 person-years in 2015 (p for trend< 0.0001). The prevalence of DIP increased from 7.3 per 100,000 persons in 2012 to 15.4 per 100,000 persons in 2015 (p for trend< 0.0001) and the incidence of DIP increased from 7.1 per 100,000 person-years in 2012 to 13.9 per 100,000 person-years in 2015 (p for trend< 0.0001). CONCLUSIONS: Our study suggests that the incidence of PD has gradually decreased whereas, the incidence of DIP increased from 2012 to 2015. Further studies are warranted to examine possible causes of increased DIP incidence in order to develop management strategy for parkinsonism.
format Online
Article
Text
id pubmed-6805681
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68056812019-10-24 Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea Han, Sola Kim, Siin Kim, Hyungtae Shin, Hae-Won Na, Kyoung-Sae Suh, Hae Sun BMC Public Health Research Article BACKGROUND: Parkinson’s disease (PD) and drug-induced parkinsonism (DIP) are the major diseases of parkinsonism. To better understand parkinsonism, we aimed to assess the prevalence and incidence of PD and DIP in Korea from 2012 to 2015. METHODS: We used the Health Insurance Review and Assessment Service database, which covers the entire population in Korea. We used claims during 2011–2015 to assess epidemiology of PD and DIP during 2012–2015. Retrospective cross-sectional study design was employed to assess prevalence, whereas retrospective cohort study design was used to determine incidence. Patients with at least one claim with ICD-10 G20 and who received antiparkinsonian drugs for at least 60 days were classified as having PD. We excluded patients with antiparkinsonian drugs that can be used for indications other than PD. Patients with at least one claim with ICD-10 G211 or G251 during the prescription period of drugs that are frequently related with DIP were classified as having DIP. Incident cases had a disease-free period of 1 year before diagnosis. To evaluate the significance of changes in the prevalence or incidence over time, Poisson regression was used to determine p for trend. RESULTS: The prevalence of PD increased from 156.9 per 100,000 persons in 2012 to 181.3 per 100,000 persons in 2015 (p for trend< 0.0001). The incidence of PD decreased steadily from 35.4 per 100,000 person-years in 2012 to 33.3 per 100,000 person-years in 2015 (p for trend< 0.0001). The prevalence of DIP increased from 7.3 per 100,000 persons in 2012 to 15.4 per 100,000 persons in 2015 (p for trend< 0.0001) and the incidence of DIP increased from 7.1 per 100,000 person-years in 2012 to 13.9 per 100,000 person-years in 2015 (p for trend< 0.0001). CONCLUSIONS: Our study suggests that the incidence of PD has gradually decreased whereas, the incidence of DIP increased from 2012 to 2015. Further studies are warranted to examine possible causes of increased DIP incidence in order to develop management strategy for parkinsonism. BioMed Central 2019-10-22 /pmc/articles/PMC6805681/ /pubmed/31640652 http://dx.doi.org/10.1186/s12889-019-7664-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Han, Sola
Kim, Siin
Kim, Hyungtae
Shin, Hae-Won
Na, Kyoung-Sae
Suh, Hae Sun
Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
title Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
title_full Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
title_fullStr Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
title_full_unstemmed Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
title_short Prevalence and incidence of Parkinson’s disease and drug-induced parkinsonism in Korea
title_sort prevalence and incidence of parkinson’s disease and drug-induced parkinsonism in korea
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805681/
https://www.ncbi.nlm.nih.gov/pubmed/31640652
http://dx.doi.org/10.1186/s12889-019-7664-6
work_keys_str_mv AT hansola prevalenceandincidenceofparkinsonsdiseaseanddruginducedparkinsonisminkorea
AT kimsiin prevalenceandincidenceofparkinsonsdiseaseanddruginducedparkinsonisminkorea
AT kimhyungtae prevalenceandincidenceofparkinsonsdiseaseanddruginducedparkinsonisminkorea
AT shinhaewon prevalenceandincidenceofparkinsonsdiseaseanddruginducedparkinsonisminkorea
AT nakyoungsae prevalenceandincidenceofparkinsonsdiseaseanddruginducedparkinsonisminkorea
AT suhhaesun prevalenceandincidenceofparkinsonsdiseaseanddruginducedparkinsonisminkorea